'김갑성' 기자의 전체기사
-
UEG 위크 2025: 최초의 인간 샘플 연구에서 미세플라스틱 노출에 따른 장내 미생물 구성…
베를린, 2025년 10월 7일 -- 우리 주변 환경에서 흔히 발견되는 5mm 미만의 플라스틱 입자인 미세플라스틱이 인간의 장내 미생물(gut microbiome)을 변화시킬 수 있고, 일부 변화는 우울증 및 대장암에서 나타나는 변화 패턴과 유사한 것으로 UEG 위크 2025(UEG Week 2025)에서 6일 발표된 새로운 연구결과를 통해 확인됐다. 씨비메드(CBmed) 연구 센터가 국제 파트너들과 협력해 주도한 선구적인 코밋(COMET) 모듈 프로그램의 일환으로 진행된 마이크로원(microONE) 프로젝트에서 수행된 본 연구는 다양한 유형의 미세플라스틱이 인간 장내 미생물과 어떻게 상호작용하는지 직접 조사한 최초의 연구에 속한다. 인체 내에서 미세 및 나노 플라스틱 입자의 영향을 탐구하겠다는 마이크로원의 광범위한 사명의 일환으로 추진된 이번 연구는 미세플라스틱이 건강에 미칠 수 있는 잠재적 영향에 대한 중요한 새로운 통찰을 제공해주는 동시에 추가 연구의 필요성이 시급함을 확인시켜준다. 연구진은 건강한 자원자 5명의 대변 샘플을 이용해 체외(ex vivo) 장내 미생물 배양을 수행했다. 이어 배양체를 폴리스티렌, 폴리프로필렌,
- 김갑성 기자
- 2025-10-07 06:01
-
MPF Powers a Mission-Critical Rebuild of Bridge2Practise: From…
SYDNEY, Oct. 7, 2025 -- Miroma Project Factory (MPF) has partnered with the University of Sydney to deliver a high-stakes, deeply technical modernisation of Bridge2Practise—a clinical skills training platform used by medical students and educators to simulate and assess procedural learning. Behind the scenes, Bridge2Practise was running on a five-year-old version of MeteorJS, linked to a deprecated database platform, with manual deployments, missing infrastructure documentation, and broken user flows. A growing backlog of bugs, performance issues, and unfulfilled feature reques
- 김갑성 기자
- 2025-10-07 05:07
-
NCCN Guidelines Navigator for Breast Cancer Genetic Testing…
[ 메디채널 김갑성 기자 ] The National Comprehensive Cancer Network expands interactive library of evidence-based, expert consensus-driven cancer care guidance to now cover treatment for more than a dozen cancer types, along with hereditary risk assessment, featuring seamless integration with additional resources. PLYMOUTH MEETING, Pa., Oct. 6, 2025 -- Today, the National Comprehensive Cancer Network® (NCCN®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN Guidelines Navigator™ resources for breast cancer treatment as well as genetic/familia
- 김갑성 기자
- 2025-10-06 21:04
-
Beacon Global Strategies Announces Dedicated Japan Off…
WASHINGTON, Oct. 6, 2025 -- Beacon Global Strategies (BGS) today announced that Dr. Zack Cooper has joined the firm as a Senior Advisor within its Indo-Pacific Practice. Dr. Cooper will play a central role in advancing BGS's work with Japanese clients and multinational companies with interests in Japan and the broader Indo-Pacific region. A recognized expert on U.S.-Japan relations, allied security cooperation, and the region's economic and geopolitical dynamics, he brings extensive experience advising clients across Tokyo, Washington, and beyond. Dr. Cooper's addition further
- 김갑성 기자
- 2025-10-06 21:00
-
Beacon Global Strategies 、日本向け専用サービスとザック・クーパー博士の…
ワシントン、2025年10月6日 --Beacon Global Strategies (BGS) は本日、ザック・クーパー 博士をインド太平洋プラクティスのシニア・アドバイザーとして迎え入れたことを発表しました。クーパー博士は、BGSが抱える日本のクライアントや、日本およびインド太平洋地域全体に関心を持つ多国籍企業との仕事を推進するうえで、中心的 な役割を担うことになります。 日米関係や同盟国の安全保障協力、そして地域における経済的・地政学的ダイナミクスの専門家として知られ、東京、ワシントン 、その他の地域のクライアントへのアドバイスについて豊富な経験を有しています。戦略的競争とビジネスの不確実性が高まるなか、BGSの能力は クーパー博士の加入によりさらに強化 され、とりわけクライアントが同盟関係の力学、地域の発展、進化する経済安全保障政策に対応できるようになります。 「中国との戦略的競争が激化し、アジアにおける協力の重要性が見直されるなか、企業はザックがこれまで一貫して提供してきたような地域に関する専門知識を必要としています。今回の彼の加入は、BGSのインド太平洋プラクティスにとって大きな前進であり、当社が持つワシントンと東京の政策決定が交錯するなかで実行可能なアドバイスを提供する能力を強化するものです」と、BGSのマネージング・デ
- 김갑성 기자
- 2025-10-06 21:00
-
Halia Therapeutics Strengthens Global Genomics Leaders…
New CSO & GM role underscores Halia's commitment to resilience-based therapeutic development and advances collaboration with the Department of Health – Abu Dhabi LEHI, Utah, Oct. 6, 2025 -- Halia Therapeutics (The Genetic Resilience Company), a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced the appointment of Paul Jones as Chief Strategy Officer & GM, International Markets. In this newly created role, Jones will focus on accelerating GENMOR-AI, the company's proprietary platform for identifying genetic mo
- 김갑성 기자
- 2025-10-06 20:15
-
Olympus and W. L. Gore & Associates Enter into International…
CENTER VALLEY, Pa., and HAMBURG, Germany, Oct. 6, 2025 -- Olympus Corporation, a global MedTech company committed to making people's lives healthier, safer and more fulfilling, has entered into an international distribution agreement with the medical products business of U.S.-based W. L. Gore & Associates, Inc. (hereinafter Gore), a global materials science company that develops innovative products across diverse industries. The agreement allows Olympus to become the exclusive international distributor and have distribution rights of the GORE® VIABIL® Biliar
- 김갑성 기자
- 2025-10-06 15:00
-
FDA Lifts Clinical Hold on NUZ-001
Highlights: U.S. FDA lifts the Clinical Hold on NUZ‑001, Neurizon®'s lead investigational therapy for ALS Clears the way for entry into the HEALEY ALS Platform Trial expected to commence in Q4 CY2025 IND supported by robust preclinical safety data and comprehensive manufacturing and quality information from the previously signed Elanco licensing agreement Expedites NUZ-001 as a platform molecule with pipeline expansion potential Positions Neurizon for accelerated regulatory pathways and future partnering opportunities MELBOURNE, Australia, Oct. 6, 2025
- 김갑성 기자
- 2025-10-06 14:06
-
Taiwan Pavilion Fostering Collaborative Innovation in AI, Rege…
TAIPEI, Oct. 6, 2025 -- The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), an organization focused on fostering Taiwan's biotech ecosystem, announced today that it will lead a delegation of 16 biotech industry partners from Taiwan to participate in BioJapan 2025 (Yokohama, October 8-10, 2025). Taiwan's participation in BioJapan 2025, through the Taiwan Pavilion and delegation, will serve as an impactful forum to showcase the value that Taiwan's ecosystem can bring to Japanese companies in jointly realizing the future of biotech innovation. BPIPO's Partici
- 김갑성 기자
- 2025-10-06 07:15
-
Hong Kong Tech Startup Advances AI Lung Cancer Screen…
HONG KONG, Oct. 4, 2025 -- Caretia, a local tech startup based at Hong Kong Science Park, today announced that its AI-powered lung cancer screening platform has achieved initial milestones and entered a new phase of development. This progress aligns closely with the direction set out in the 2025 Policy Address, where Chief Executive Mr. John Lee indicated that the government would comprehensively enhance cancer prevention and diagnosis and specifically recommended launching AI-assisted lung cancer screening. According to data from the HK Cancer Online Resource Hub, lung cancer
- 김갑성 기자
- 2025-10-04 08:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 16시 40분